Cargando…

One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli

BACKGROUND: Human α-synuclein is a small-sized, natively unfolded protein that in fibrillar form is the primary component of Lewy bodies, the pathological hallmark of Parkinson’s disease. Experimental evidence suggests that α-synuclein aggregation is the key event that triggers neurotoxicity althoug...

Descripción completa

Detalles Bibliográficos
Autores principales: Caldinelli, Laura, Albani, Diego, Pollegioni, Loredano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621789/
https://www.ncbi.nlm.nih.gov/pubmed/23557146
http://dx.doi.org/10.1186/1472-6750-13-32
_version_ 1782265761911275520
author Caldinelli, Laura
Albani, Diego
Pollegioni, Loredano
author_facet Caldinelli, Laura
Albani, Diego
Pollegioni, Loredano
author_sort Caldinelli, Laura
collection PubMed
description BACKGROUND: Human α-synuclein is a small-sized, natively unfolded protein that in fibrillar form is the primary component of Lewy bodies, the pathological hallmark of Parkinson’s disease. Experimental evidence suggests that α-synuclein aggregation is the key event that triggers neurotoxicity although additional findings have proposed a protective role of α-synuclein against oxidative stress. One way to address the mechanism of this protective action is to evaluate α-synuclein-mediated protection by delivering this protein inside cells using a chimeric protein fused with the Tat-transduction domain of HIV Tat, named TAT-α-synuclein. RESULTS: A reliable protocol was designed to efficiently express and purify two different forms of human α-synuclein. The synthetic cDNAs encoding for the native α-synuclein and the fusion protein with the transduction domain of Tat protein from HIV were overexpressed in a BL21(DE3) E. coli strain as His-tagged proteins. The recombinant proteins largely localized (≥ 85%) to the periplasmic space. By using a quick purification protocol, based on recovery of periplasmic space content and metal-chelating chromatography, the recombinant α-synuclein protein forms could be purified in a single step to ≥ 95% purity. Both α-synuclein recombinant proteins form fibrils and the TAT-α-synuclein is also cytotoxic in the micromolar concentration range. CONCLUSIONS: To further characterize the molecular mechanisms of α-synuclein neurotoxicity both in vitro and in vivo and to evaluate the relevance of extracellular α-synuclein for the pathogenesis and progression of Parkinson’s disease, a suitable method to produce different high-quality forms of this pathological protein is required. Our optimized expression and purification procedure offers an easier and faster means of producing different forms (i.e., both the native and the TAT-fusion form) of soluble recombinant α-synuclein than previously described procedures.
format Online
Article
Text
id pubmed-3621789
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36217892013-04-10 One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli Caldinelli, Laura Albani, Diego Pollegioni, Loredano BMC Biotechnol Research Article BACKGROUND: Human α-synuclein is a small-sized, natively unfolded protein that in fibrillar form is the primary component of Lewy bodies, the pathological hallmark of Parkinson’s disease. Experimental evidence suggests that α-synuclein aggregation is the key event that triggers neurotoxicity although additional findings have proposed a protective role of α-synuclein against oxidative stress. One way to address the mechanism of this protective action is to evaluate α-synuclein-mediated protection by delivering this protein inside cells using a chimeric protein fused with the Tat-transduction domain of HIV Tat, named TAT-α-synuclein. RESULTS: A reliable protocol was designed to efficiently express and purify two different forms of human α-synuclein. The synthetic cDNAs encoding for the native α-synuclein and the fusion protein with the transduction domain of Tat protein from HIV were overexpressed in a BL21(DE3) E. coli strain as His-tagged proteins. The recombinant proteins largely localized (≥ 85%) to the periplasmic space. By using a quick purification protocol, based on recovery of periplasmic space content and metal-chelating chromatography, the recombinant α-synuclein protein forms could be purified in a single step to ≥ 95% purity. Both α-synuclein recombinant proteins form fibrils and the TAT-α-synuclein is also cytotoxic in the micromolar concentration range. CONCLUSIONS: To further characterize the molecular mechanisms of α-synuclein neurotoxicity both in vitro and in vivo and to evaluate the relevance of extracellular α-synuclein for the pathogenesis and progression of Parkinson’s disease, a suitable method to produce different high-quality forms of this pathological protein is required. Our optimized expression and purification procedure offers an easier and faster means of producing different forms (i.e., both the native and the TAT-fusion form) of soluble recombinant α-synuclein than previously described procedures. BioMed Central 2013-04-04 /pmc/articles/PMC3621789/ /pubmed/23557146 http://dx.doi.org/10.1186/1472-6750-13-32 Text en Copyright © 2013 Caldinelli et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Caldinelli, Laura
Albani, Diego
Pollegioni, Loredano
One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli
title One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli
title_full One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli
title_fullStr One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli
title_full_unstemmed One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli
title_short One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli
title_sort one single method to produce native and tat-fused recombinant human α-synuclein in escherichia coli
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621789/
https://www.ncbi.nlm.nih.gov/pubmed/23557146
http://dx.doi.org/10.1186/1472-6750-13-32
work_keys_str_mv AT caldinellilaura onesinglemethodtoproducenativeandtatfusedrecombinanthumanasynucleininescherichiacoli
AT albanidiego onesinglemethodtoproducenativeandtatfusedrecombinanthumanasynucleininescherichiacoli
AT pollegioniloredano onesinglemethodtoproducenativeandtatfusedrecombinanthumanasynucleininescherichiacoli